Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 0.62% and closed at $1.62, with the total traded volume of 0.00 shares. During last trade its minimum price was $1.61 and it gained its highest price of $1.68 and has a total of 40.91 million outstanding shares.
On March 14, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc. the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products.
Ms. Foster-Cunningham’s immediate focus is preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.)
Ms. Foster-Cunningham, whom holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is “her new baby”.
“I love my work, especially when it allows me to bring my passion for health and business development together, and to bring them to other people,’ says Foster-Cunningham. “This project is my new baby, and I’m excited about the prospects of helping it grow to maturity.”
General Cannabis Corp (OTCMKTS:CANN) showing jumped of 7.56% and closed at $2.42, after gaining total volume of 0.00 shares. Its earnings per share (EPS) is -$1.23 and its beta value stands at -34.66 points and has total market capitalization of $39.04 million and a total of 15.74 million outstanding shares.
General Cannabis Corp. provides services to the regulated cannabis industry in the United States. The company engages in the acquisition and leasing of cultivation space and related facilities to licensed marijuana growers and dispensary owners; and provision of security services, including on-site professionals, video surveillance, and cash transport to licensed cannabis cultivators and retail shops. It also designs, distributes, and sells apparel featuring graphic designs; and offers consulting services to the cannabis industry that comprise obtaining licenses, compliance, cultivation, logistical support, facility design, and building services. In addition, General Cannabis Corp. provides shared office space, networking, and event services; and leases cultivation equipment and facilities. The company was formerly known as Advanced Cannabis Solutions, Inc. and changed its name to General Cannabis Corp. in June 2015. General Cannabis Corp. was founded in 2013 and is headquartered in Denver, Colorado.
AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) increased 0.40% closed at $1.95 and traded with total volume of 0.00 shares, while the average trading remained 639,292.00 shares. During last trade its minimum price was $1.90 and it gained the highest price of $2.00. Its market capitalization was $541.30 million.
AURORA CANNABIS IN COM NPV (ACBFF) on January 26, 2017 announced that it has entered into an amending agreement with a syndicate of underwriters led by Canaccord Genuity Corp. (collectively, the “Underwriters”) to increase the size of its previously announced private placement offering. Pursuant to the revised terms of the offering, the Underwriters have agreed to purchase, on a bought deal private placement basis, 26,670,000 units of the Company (the “Units”), at a price of $2.25 per Unit (the “Offering Price”) for aggregate gross proceeds to Aurora of $60,007,500.00 (the “Offering”).
The Company has granted the Underwriters an option (the “Underwriters’ Option”), exercisable in whole or in part up to 48 hours prior to the closing of the Offering, to purchase up to 6,667,500 additional Units of the Company at the Offering Price. If the underwriters’ Option is exercised in full the aggregate gross proceeds of the Offering will be $75,009,375.
Each Unit will be comprised of one common share of the Company (a “Common Share”) and half of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one Common Share (a “Warrant Share”) for a period of two years following the closing date of the Offering at an exercise price of $3.00 per Warrant Share, subject to adjustment in certain events. The Warrants will be subject to a forced exercise provision if the Company’s daily volume weighted average share price on the TSX Venture Exchange (or such other stock exchange the Company may be trading on) is greater than $4.50 for 10 consecutive trading days following the date that is four months and one day following the closing of the Offering. Net proceeds from the Offering will be used primarily towards the Company’s strategic growth initiatives including its planned facility expansion, and for general working capital purposes.